FLEMINGTON, N.J., May 29, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Glenn Mattes is scheduled to present at the Jefferies 2014 Global Healthcare Conference being held June 2-5, 2014 in New York, NY.
Mr. Mattes will present on Thursday, June 5, 2014 at 10:30 a.m. EDT to attending investors. During his presentation, Mr. Mattes will discuss Arno's business and growth strategy, ongoing clinical development of its lead candidate and personalized oncology therapy, onapristone, and the accompanying companion diagnostic. Mr. Mattes will also discuss recent milestones, including the start of Arno's clinical trials for onapristone in women with progesterone receptor positive tumors and in men with advanced castration-resistant prostate cancer.
Details of the presentation are as follows:
| Date: | Thursday, June 5, 2014 |
| Time: | 10:30 a.m. EDT |
| Track: | Track 6 |
Investors attending the Conference who would like to schedule a 1-on-1 meeting with Arno management may do so by contacting their Jefferies representative, or Lee Roth of The Ruth Group at lroth@theruthgroup.com.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information about the company, please visit www.arnothera.com.